European Archives - Page 483 of 1166 - European Medical Journal

Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine

Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).

Stromal Tumour Post-Roux-en-Y Gastric Bypass

To the authors’ knowledge, only two cases of gastric gastrointestinal stromal tumours after Roux-en-Y gastric bypass have been reported in medical literature, it is an extremely rare condition to occur after bariatric surgery…

EMJ

Infographic: Perceptions of Treatments in AML – A Survey of 375 European Haematologists

Acute myeloid leukaemia (AML) is a rapidly progressing haematological cancer with a poor prognosis. This infographic summarises the key results from an online survey conducted in 2022 on the perceptions of AML treatments among clinicians in Europe. Haematologists and oncologists from five European countries were asked their opinions on topics such as first-line treatments, the intensity of treatment regimens, and therapies for curative intent for patients with AML.

Phenotypes of Post-COVID-19 Interstitial Lung Disease: Clinical, Radiological and Pathological Correlations

This webinar will discuss the findings of a recent multicenter, prospective study that monitored patients with previous COVID-19 related pneumonia over time to understand the evolution of the disease. The findings of the study and the follow-up which included respiratory function tests, chest CT, and cryobiopsy will be examined and discussed.

World AIDS Day 2022 special

Helena and Isabel share a very special episode to mark World AIDS Day, featuring Dr Nneka Nwokolo, Global Head of Patient Affairs at ViiV.

DOACs in Review - How did we get here?

This upcoming webinar discussion shares clinical insights from an expert in the use of direct oral anticoagulants for the treatment of…

Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.

EMJ Respiratory 10 [Supplement 2] 2022

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.

Dilemmas in breast cancer treatment planning: how understanding tumor biology with MammaPrint and BluePrint can help you

This webinar will educate you on how the biology of a breast tumour reveals additional information that can support choosing the best treatment plan. It will specifically focus on now-a-days clinical dilemmas, like what is the best treatment for pre-menopausal patients, what is the optimal duration of endocrine therapy and how can I find those nasty tumours. The dilemmas are discussed with the help of cases.

Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

As part of the 31st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7th–10th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines.